Dr. Nanxing is CEO and Managing Partner at Shenzhen Sangel Capital Management Co., Ltd., a firm focusing on investing in innovative startups in the healthcare field and having RMB and USD funds under management. With over ten years’ venture capital experience, Nanxing has led investments in a significant number of companies in China and the U.S., including Ascentawits, BeyondSpring, 3DMed, Huaheng Bio, Aucta, Denovo Biopharma, Sirnaomics, IntelliBio, Predicine, etc. Nanxing also serves on the Board of Directors of multiple Sangel’s portfolios. Nanxing received her Ph.D. from the University of Nottingham and an MBA from Cranfield School of Management.